GeneDx Quote - WGS

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

77.18

Bid

74.25

Ask

80.01

Volume

1,267,941

74.45 Day's Range 78.49

3.901 52 Week Range 98.87

Market Cap

2.12B

Previous Close

78.00

Open

77.39

Last Trade

Last Trade Time

Financial Volume

US$ 97,476,250

VWAP

76.8776

Average Volume (3m)

809,778

Shares Outstanding

27,471,397

Dividend Yield

PE Ratio

-11.94

Earnings Per Share (EPS)

-6.4

Revenue

202.57M

Net Profit

-175.77M

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and... GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut. Show more

Sector

Blank Checks

Industry

Health Services

Website

www.genedx.com

Headquarters

Wilmington, Delaware, USA

Founded

2020

GeneDx Holdings Corporation is listed in the Blank Checks sector of the NASDAQ with ticker WGS. The last closing price for GeneDx was US$78. Over the last year, GeneDx shares have traded in a share price range of US$ 3.901 to US$ 98.87.

GeneDx currently has 27,471,397 shares outstanding. The market capitalization of GeneDx is US$2.14 billion. GeneDx has a price to earnings ratio (PE ratio) of -11.94.

Overall Flow

Bullish

Net Premium

2M

Calls / Puts

69.05%

Buys / Sells

70.73%

OTM / ITM

162.96%

Sweeps Ratio

4.23%

GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients

ultraRapid testing addresses the underutilization of testing in the NICU and can lead to more than $15K in healthcare savings per child GeneDx...

GeneDx to Participate in 45th Annual TD Cowen Health Care Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will...

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic Suite GeneDx (Nasdaq: WGS), a...

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced it will release financial results for...

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as...

GeneDx Announces Preliminary 2024 Financial Results

Expects to exceed guidance with full year 2024 revenues1 of at least $299 million Expects fourth quarter 2024 revenues1 of at least $92 million...

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic...

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 GeneDx...

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs...

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	14.96	24.043715847	62.22	78.7675	58.62	1333737	69.24948849	CS
4	7.54	10.8271108558	69.64	82.49	58.62	1124211	70.37287881	CS
12	4.63	6.38180565127	72.55	98.87	58.62	809778	75.50819276	CS
26	42.86	124.883449883	34.32	98.87	28.86	667592	66.99680471	CS
52	73.18	1829.5	4	98.87	3.901	541637	49.74569281	CS
156	66.257	606.582440721	10.923	98.87	1.16	952483	22.0642367	CS
260	66.257	606.582440721	10.923	98.87	1.16	952483	22.0642367	CS

WGS - Frequently Asked Questions (FAQ)

What is the current GeneDx share price?

The current share price of GeneDx is US$ 77.18

How many GeneDx shares are in issue?

GeneDx has 27,471,397 shares in issue

What is the market cap of GeneDx?

The market capitalisation of GeneDx is USD 2.14B

What is the 1 year trading range for GeneDx share price?

GeneDx has traded in the range of US$ 3.901 to US$ 98.87 during the past year

What is the PE ratio of GeneDx?

The price to earnings ratio of GeneDx is -11.94

What is the cash to sales ratio of GeneDx?

The cash to sales ratio of GeneDx is 10.36

What is the reporting currency for GeneDx?

GeneDx reports financial results in USD

What is the latest annual turnover for GeneDx?

The latest annual turnover of GeneDx is USD 202.57M

What is the latest annual profit for GeneDx?

The latest annual profit of GeneDx is USD -175.77M

What is the registered address of GeneDx?

The registered address for GeneDx is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the GeneDx website address?

The website address for GeneDx is www.genedx.com

Which industry sector does GeneDx operate in?

GeneDx operates in the HEALTH SERVICES sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
JTAIJet AI Inc	US$ 6.02 (133.33%)	104.48M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	254.39M
WRDWeRide Inc	US$ 31.4877 (83.39%)	21.07M
INLFINLIF Limited	US$ 16.27 (80.58%)	7.68M
MBRXMoleculin Biotech Inc	US$ 2.1201 (66.94%)	136.66M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3.08 (-56.31%)	425.19k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3.36 (-52.68%)	5.21k
CSAICloudastructure Inc	US$ 19.0001 (-49.58%)	1.01M
NEXNNexxen International Ltd	US$ 10.30 (-49.16%)	160.99k
BSLKBolt Projects Holdings Inc	US$ 0.6626 (-46.13%)	13.07M
CNSPCNS Pharmaceuticals Inc	US$ 0.1415 (31.26%)	480.49M
MGOLMGO Global Inc	US$ 0.7176 (-15.08%)	411.17M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	248.48M
INTCIntel Corporation	US$ 23.60 (-2.20%)	225.04M
NVDANVIDIA Corporation	US$ 138.85 (2.63%)	189.56M